Seeking Alpha

MannKind (MNKD -11.8%) shares plummet after the company reports a Q1 loss and says its...

MannKind (MNKD -11.8%) shares plummet after the company reports a Q1 loss and says its end-of-review meeting with the FDA over its inhaled insulin Afrezza was productive. But trials will run through at least late 2012, and cash could run out by then. "It is not an overstatement to say that everything is riding on the future regulatory and commercial success of Afrezza," a Baird analyst says.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|